Research programme: allogeneic cell therapy - StemCyte
Latest Information Update: 08 Sep 2021
At a glance
- Originator StemCyte
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 04 Aug 2021 Early research in Cancer in USA (Parenteral)